Characteristic/category | Number examined | Number anaemic (%) | Bivariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|---|
OR (95 % CI) | p-value$ | OR (95 % CI) | p-value£ | |||
Age group (years) | ||||||
  < 5 | 66 | 22 (33.3) | 0.36 (0.17–0.77) | 0.014* | 0.68 (0.25–1.87) | 0.45 |
 5–10 | 120 | 66 (55.0) | 0.87 (0.44–1.72) | 0.825 | 0.74 (0.34–1.62) | 0.45 |
 11–15 | 48 | 28 (58.3) | Reference |  |  |  |
Sex | ||||||
 Female | 138 | 74 (53.6) | 1.49 (0.88–2.51) | 0.176 | 2.15 (1.11–4.15) | 0.024* |
 Male | 96 | 42 (43.7) | Reference |  |  |  |
Presence of fever | ||||||
 No | 220 | 104 (47.3) | Reference |  |  |  |
 Yes | 14 | 12 (85.7) | 6.69 (1.46–30.60) | 0.012* | 3.65 (0.69–19.20) | 0.13 |
CD4 T Cell category (cells/μl) | ||||||
  < 200 | 28 | 16 (57.1) | 2.10 (0.92–4.76) | 0.114 | 1.99 (0.76–5.18) | 0.16 |
 200–499 | 44 | 32 (72.7) | 4.19 (1.99–8.81) | 0.00017* | 3.79 (1.68–8.52) | 0.0013* |
  ≥ 500 | 144 | 56 (38.9) | Reference |  |  |  |
Clinical stages | ||||||
 Stage 1 | 44 | 18 (40.9) | 0.48 (0.12–1.20) | 0.180 | 0.73 (0.24–2.17) | 0.57 |
 Stage 2 | 62 | 34 (54.8) | 0.85 (0.36–1.98) | 0.87 | 0.97 (0.35–2.64) | 0.95 |
 Stage 3 | 82 | 36 (43.9) | 0.55 (0.24–1.23) | 0.21 | 0.45 (0.18–1.15) | 0.09 |
 Stage 4 | 34 | 20 (58.8) | Reference |  |  |  |
Use of ART | ||||||
 No | 52 | 30 (57.7) | 1.52 (0.82–2.84) | 0.242 | 1.29 (0.60–1.29) | 0.51 |
 Yes | 182 | 86 (47.3) | Reference |  |  |  |